Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWATCH: ATG-010 + R2 in R/R DLBCL and iNHL
NCT05265975Phase 2Terminated
- Sponsor
- Antengene
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in diffuse large B-cell lymphoma (DLBCL) and Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Antengene. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 28 days. Started Apr 2022; status: terminated.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT05265975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265975.